echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Innovative drugs usher in the harvest period, and Chinese pharmaceutical companies become new forces in global pharmaceutical research and development

    Innovative drugs usher in the harvest period, and Chinese pharmaceutical companies become new forces in global pharmaceutical research and development

    • Last Update: 2019-12-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [industry trends of pharmaceutical network] a while ago, Baiji Shenzhou announced that its Btk inhibitor zebutini independently researched and developed by itself had passed the approval of the US Food and Drug Administration (FDA), becoming the first new anti-cancer drug independently researched and developed by Chinese enterprises and approved to be listed in the US In fact, zebutini's success in going to sea is the epitome of Chinese local pharmaceutical enterprises from "Introduction" to "going out" Photo source: pharmaceutical network's independent research and development of innovative drugs ushered in the harvest period, and pharmaceutical companies have planned to go to sea At present, with the help of policies, China's innovative drug research and development is in full swing, and has entered the golden harvest period In this way, the first original new drug for Alzheimer's disease in China, ganlute sodium capsule, has the conditions to be approved for listing, which fills the gap that there is no new drug in this field in the world for 17 years In addition, sidabamide, which has recently been officially approved by the National Drug Administration (nmpa) as a new indication for the treatment of advanced breast cancer and metastatic breast cancer, is also independently developed and produced by Shenzhen micro core Biotechnology Co., Ltd After the harvest of independent research and development of innovative drugs, Chinese innovative drugs began to plan to go to sea At present, 9 domestic class 1 new drug syndromes, including carrelion monoclonal antibody of Hengrui medicine and conbercept of Kanghong pharmaceutical industry, are in phase III clinical stage in the world, with 41 clinical trials in total The indications are mainly in the field of anti-tumor These new drugs under research are typical representatives of domestic new drugs, which are expected to submit listing applications or complete clinical trials in the United States, so as to promote domestic innovative drugs from domestic to global Local innovative pharmaceutical companies have provided a boost for global pharmaceutical research and development It has been reported that from 2016 to 2018, China's contribution rate jumped from 4.1% to 7.8% in the proportion of pre development products to the world After the number of new drugs listed on the world market, China's contribution rate jumped from 2.5% to 4.6%, and has entered the second tier of global pharmaceutical innovation This can also be seen from more and more cases of foreign biomedical companies introducing overseas rights and interests of Chinese pharmaceutical companies in independent research and development of innovative drugs, and more and more transaction amount For example, as early as 2013, Baiji Shenzhou granted Merck the right to develop and sell the global market of small molecule drugs under research, with a price of 233 million US dollars Since 2015, the licensing of local innovative medicines has become increasingly frequent In addition to Baiji Shenzhou, there are three McAbs transferred by Cinda bio to Lilly, and international development license of anti hepatitis B drugs outside mainland China transferred by Zhengda Tianqing to Johnson & Johnson, etc Domestic innovative medicine has become the general trend, and multinational pharmaceutical enterprises have joined in succession From the perspective of people's demand and industry upgrading, it is the general trend to make innovative medicine in China Both local enterprises and foreign enterprises in China have realized this clearly Especially in recent years, under the influence of domestic policy measures such as consistency evaluation, medical insurance fee control, "4 + 7" volume procurement, medical catalog negotiation, multinational pharmaceutical enterprises have adjusted their strategies in China Especially this year, in order to stabilize or even further speed up its layout in China, many multinational pharmaceutical companies frequently act For example, recently, Roche Shanghai innovation center with an investment of 863 million yuan was completed in Zhangjiang, Shanghai, with a total area of 26000 square meters, replacing Roche's first R & D center in emerging markets in 2004 At present, the center has about 150 researchers, more than 90% of whom are local scientists In addition, AstraZeneca announced to upgrade its existing Shanghai R & D platform to a global R & D center at the just concluded 2nd China International Import Expo, and set up an artificial intelligence innovation center in Shanghai In addition, bringer Ingelheim announced that the "German technology + Zhangjiang manufacturing" biopharmaceutical commercial contract production (CMO) service platform was built in Shanghai, which proves that multinational pharmaceutical companies are interested in the layout of innovative drug research and development in China At present, many multinational pharmaceutical companies have disclosed their new drug listing plans in China In the next 5-10 years, more than 5 multinational pharmaceutical companies are expected to submit 10-60 new drug applications in China In fact, both the "zero breakthrough" of local enterprises and the "new growth" of foreign enterprises in China have proved the strong support of the state for the development of innovative drugs It also proves that China has taken a solid step from a big country of generic drugs to a big country of innovative drugs.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.